Geode Capital Management
LXEO icon

Geode Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Geode Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.69M Buy
1,513,777
+67,890
+5% +$481K ﹤0.01% 2459
2025
Q4 		$14.4M Buy
1,445,887
+724,006
+100% +$6.61M ﹤0.01% 2198
2025
Q3 		$4.79M Buy
721,881
+143,800
+25% +$695K ﹤0.01% 2804
2025
Q2 		$2.32M Sell
578,081
-8,435
-1% -$27.7K ﹤0.01% 3091
2025
Q1 		$2.04M Buy
586,516
+19,133
+3% +$84.8K ﹤0.01% 3021
2024
Q4 		$3.73M Buy
567,383
+14,136
+3% +$111K ﹤0.01% 2878
2024
Q3 		$5M Buy
553,247
+256,635
+87% +$3.06M ﹤0.01% 2759
2024
Q2 		$4.76M Buy
296,612
+98,813
+50% +$1.44M ﹤0.01% 2754
2024
Q1 		$3.1M Buy
197,799
+97,378
+97% +$1.52M ﹤0.01% 2934
2023
Q4 		$1.35M Buy
+100,421
New +$1.25M ﹤0.01% 3228

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management's LXEO Position: Q1 2026 in Review

Geode Capital Management increased its Lexeo Therapeutics (LXEO) stake by 4.7% in Q1 2026, buying an estimated $481K and bringing the position to 1,513,777 shares worth $8.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2459.

Geode Capital Management first reported a position in LXEO in Q4 2023 and has held it in 10 quarters since. The position peaked at $14.4M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Geode Capital Management held 1,513,777 shares of Lexeo Therapeutics worth $8.69M as of Q1 2026.
  • Geode Capital Management bought 67,890 Lexeo Therapeutics shares in Q1 2026, an estimated $481K.
  • Lexeo Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2459 holding.
  • Geode Capital Management first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Geode Capital Management's Lexeo Therapeutics position peaked at $14.4M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.